Giant gastrointestinal stromal tumor of the jejunum resected after treatment with imatinib

• Published in: International cancer conference journal Vol. 1; no. 1; pp. 41 - 46
• Main Authors: Shigemitsu, Kaori, Yamada, Takako, Kinoshita, Shinichiro, Takaoka, Munenori, Fukazawa, Takuya, Hayashi, Jiro, Yoshida, Kazuhiro, Yamatsuji, Tomoki, Morita, Ichiro, Monobe, Yasumasa, Naomoto, Yoshio
• Format: Journal Article
• Language: English
• Published: Japan Springer Japan 01.03.2012; Springer Nature B.V
• Subjects: Abdomen; Biopsy; c-Kit protein; Case Report; Chemotherapy; Computed tomography; Gastrointestinal cancer; Gene deletion; Genetic analysis; Hospitals; Imatinib; Jejunum; Kinases; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Mitosis; Mutation; Oncology; Patients; Small intestine; Surgery; Surgical Oncology; Tumor cells; Tumors; Surgical intervention; Multimodal therapy; Gastrointestinal stromal tumor
• ISSN: 2192-3183; 2192-3183
• DOI: 10.1007/s13691-011-0007-9

Unresectable, metastatic, recurrent gastrointestinal stromal tumor (GIST) is primarily treated with a molecular-targeted therapeutic agent, imatinib. However, after an initial response, a secondary resistance to the drug often occurs after a few years. We report here a case of a resected giant GIST of the jejunum that disseminated following treatment with imatinib. A 59-year-old male presented with a giant tumor in the abdominal cavity, which was diagnosed as GIST by needle biopsy; he was administered 400 mg/day imatinib. Eight months later, the tumor had considerably decreased, but multiple tumors in the small intestine and mesenterium, indicating dissemination, appeared. Administration of imatinib was continued, and the dissemination gradually reduced and almost disappeared except for a tumor in the right upper abdomen. Three years later, follow-up computed tomography revealed that the disseminated lesions had enlarged; a part of the intrapelvic tumor was suspected to be viable. We deduced that the tumor developed partial resistance to imatinib: therefore, we surgically removed as many disseminated tumors as possible. Pathologically, resected tumors appeared to have no viable tumor cells except for a small part of the primary tumor in which mitosis was 0–1/50 high-power fields. Genetic analysis of c-Kit mutation revealed an exon 11 c554–559 deletion. The patient remained recurrence-free for 10 months after surgery. When partial resistance to imatinib is observed, combined modality therapy that involves chemotherapy with surgical intervention at early stages is expected to improve the outcome.